FDA OKs Inotersen for Hereditary ATTR With Polyneuropathy
Inotersen treatment led to improvements in neurologic and quality-of-life endpoints in patients with hereditary transthyretin amyloidosis with polyneuropathy in a pivotal phase 3 trial. FDA Approvals …read more